237 related articles for article (PubMed ID: 35887308)
1. Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism.
Zügner E; Yang HC; Kotzbeck P; Boulgaropoulos B; Sourij H; Hagvall S; Elmore CS; Esterline R; Moosmang S; Oscarsson J; Pieber TR; Peng XR; Magnes C
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887308
[TBL] [Abstract][Full Text] [Related]
2. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na
Uthman L; Baartscheer A; Bleijlevens B; Schumacher CA; Fiolet JWT; Koeman A; Jancev M; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
Diabetologia; 2018 Mar; 61(3):722-726. PubMed ID: 29197997
[TBL] [Abstract][Full Text] [Related]
3. Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells.
Uthman L; Kuschma M; Römer G; Boomsma M; Kessler J; Hermanides J; Hollmann MW; Preckel B; Zuurbier CJ; Weber NC
Cardiovasc Drugs Ther; 2021 Dec; 35(6):1083-1094. PubMed ID: 33048256
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous LC-MS/MS quantification of SGLT2 inhibitors and antipyrine in medium and tissue from human ex vivo placenta perfusions.
Kuoni S; Müller D; Simões-Wüst AP; Steiner R
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Aug; 1228():123841. PubMed ID: 37542935
[TBL] [Abstract][Full Text] [Related]
5. Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?
Nikolaou PE; Mylonas N; Makridakis M; Makrecka-Kuka M; Iliou A; Zerikiotis S; Efentakis P; Kampoukos S; Kostomitsopoulos N; Vilskersts R; Ikonomidis I; Lambadiari V; Zuurbier CJ; Latosinska A; Vlahou A; Dimitriadis G; Iliodromitis EK; Andreadou I
Basic Res Cardiol; 2022 May; 117(1):27. PubMed ID: 35581445
[TBL] [Abstract][Full Text] [Related]
6. Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: An ex vivo human placenta perfusion and in vitro study.
Kuoni S; Steiner R; Saleh L; Lehmann R; Ochsenbein-Kölble N; Simões-Wüst AP
Biomed Pharmacother; 2024 Feb; 171():116177. PubMed ID: 38262151
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 Inhibitor Canagliflozin Alleviates High Glucose-Induced Inflammatory Toxicity in BV-2 Microglia.
Lee CT; Lin KD; Hsieh CF; Wang JY
Biomedicines; 2023 Dec; 12(1):. PubMed ID: 38255143
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness in the inhibition of dapagliflozin and canagliflozin on M-type K
So EC; Liu PY; Wu SN
Eur J Pharmacol; 2020 Jul; 879():173141. PubMed ID: 32353360
[TBL] [Abstract][Full Text] [Related]
9. Sodium Glucose Co-Transporter 2 Inhibitors Ameliorate Endothelium Barrier Dysfunction Induced by Cyclic Stretch through Inhibition of Reactive Oxygen Species.
Li X; Römer G; Kerindongo RP; Hermanides J; Albrecht M; Hollmann MW; Zuurbier CJ; Preckel B; Weber NC
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34205045
[TBL] [Abstract][Full Text] [Related]
10. The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1α signalling pathway.
Yang X; Liu Q; Li Y; Tang Q; Wu T; Chen L; Pu S; Zhao Y; Zhang G; Huang C; Zhang J; Zhang Z; Huang Y; Zou M; Shi X; Jiang W; Wang R; He J
Adipocyte; 2020 Dec; 9(1):484-494. PubMed ID: 32835596
[TBL] [Abstract][Full Text] [Related]
11. Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT).
Nakano D; Kawaguchi T; Iwamoto H; Hayakawa M; Koga H; Torimura T
PLoS One; 2020; 15(4):e0232283. PubMed ID: 32343721
[TBL] [Abstract][Full Text] [Related]
12. Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells.
Uthman L; Homayr A; Juni RP; Spin EL; Kerindongo R; Boomsma M; Hollmann MW; Preckel B; Koolwijk P; van Hinsbergh VWM; Zuurbier CJ; Albrecht M; Weber NC
Cell Physiol Biochem; 2019; 53(5):865-886. PubMed ID: 31724838
[TBL] [Abstract][Full Text] [Related]
13. Distinctive effects of SGLT2 inhibitors on angiogenesis in zebrafish embryos.
Huttunen R; Sainio A; Hjelt A; Haapanen-Saaristo AM; Määttä J; Rummukainen P; Paatero I; Järveläinen H
Biomed Pharmacother; 2022 Dec; 156():113882. PubMed ID: 36265308
[TBL] [Abstract][Full Text] [Related]
14. Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells.
Satou R; Cypress MW; Woods TC; Katsurada A; Dugas CM; Fonseca VA; Navar LG
Am J Physiol Renal Physiol; 2020 Jan; 318(1):F67-F75. PubMed ID: 31682172
[TBL] [Abstract][Full Text] [Related]
15. Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States.
Cai J; Divino V; Burudpakdee C
Curr Med Res Opin; 2017 Jul; 33(7):1317-1328. PubMed ID: 28418262
[TBL] [Abstract][Full Text] [Related]
16. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats.
Durak A; Olgar Y; Degirmenci S; Akkus E; Tuncay E; Turan B
Cardiovasc Diabetol; 2018 Nov; 17(1):144. PubMed ID: 30447687
[TBL] [Abstract][Full Text] [Related]
17. Differential effect of canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice.
Otsuka H; Yokomizo H; Nakamura S; Izumi Y; Takahashi M; Obara S; Nakao M; Ikeda Y; Sato N; Sakamoto R; Miyachi Y; Miyazawa T; Bamba T; Ogawa Y
Biochem J; 2022 Feb; 479(3):425-444. PubMed ID: 35048967
[TBL] [Abstract][Full Text] [Related]
18. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
Chu C; Lu YP; Yin L; Hocher B
Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
[TBL] [Abstract][Full Text] [Related]
19. SGLT2-independent effects of canagliflozin on NHE3 and mitochondrial complex I activity inhibit proximal tubule fluid transport and albumin uptake.
Albalawy WN; Youm EB; Shipman KE; Trull KJ; Baty CJ; Long KR; Rbaibi Y; Wang XP; Fagunloye OG; White KA; Jurczak MJ; Kashlan OB; Weisz OA
Am J Physiol Renal Physiol; 2024 Jun; 326(6):F1041-F1053. PubMed ID: 38660713
[TBL] [Abstract][Full Text] [Related]
20. Sex-dependent effects of canagliflozin and dapagliflozin on hemostasis in normoglycemic and hyperglycemic mice.
Marcińczyk N; Misztal T; Chabielska E; Gromotowicz-Popławska A
Sci Rep; 2023 Jan; 13(1):932. PubMed ID: 36650229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
